Nasal cavity squamous cell carcinoma

Summary

Nasal cavity squamous cell carcinoma (MONDO:0006059) is a cancer and 3 clinical trials. Top therapeutic interventions include cisplatin, atezolizumab, and cetuximab. A subtype of nasal cavity carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity squamous cell carcinoma
Mondo ID	MONDO:0006059
EFO	EFO:1000057
DOID	DOID:5515
NCIT	C8192
UMLS	C0280333
MedGen	79104
GARD	0024278
Anatomy (UBERON)	UBERON:0001707
Is cancer (heuristic)	yes

Also known as: nasal cavity squamous cell carcinoma · squamous cell carcinoma of nasal cavity · squamous cell carcinoma of the nasal cavity

Data availability: 4 cell lines.

Disease family

This is a subtype of nasal cavity carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › nasal cavity cancer › nasal cavity carcinoma › nasal cavity squamous cell carcinoma

Related subtypes (3): nasal cavity adenocarcinoma, nasal cavity carcinoma in situ, carcinoma arising in nasal papillomatosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05063552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT06980038	PHASE2	RECRUITING	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT05172245	PHASE1	RECRUITING	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	2
ATEZOLIZUMAB	4	1
CETUXIMAB	4	1
IPATASERTIB	3	1
CHEMBL5412235	0	1